Pacific Biosciences of California, Inc. Stock Börse Stuttgart

Equities

P09

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Börse Stuttgart 10:14:12 2024-06-28 EDT 5-day change 1st Jan Change
1.26 EUR +2.37% Intraday chart for Pacific Biosciences of California, Inc. -8.16% -86.31%

Financials

Sales 2024 * 180M 168M 246M Sales 2025 * 234M 219M 321M Capitalization 373M 348M 510M
Net income 2024 * -255M -238M -349M Net income 2025 * -202M -189M -276M EV / Sales 2024 * 4.49 x
Net Debt 2024 * 434M 405M 593M Net Debt 2025 * 469M 438M 642M EV / Sales 2025 * 3.59 x
P/E ratio 2024 *
-1.46 x
P/E ratio 2025 *
-1.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.1%
More Fundamentals * Assessed data
Dynamic Chart
PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry MT
Form Bio and Pacbio Announce Collaboration to Launch New Resources Set to Transform Aav Design and Analysis Best Practices CI
PacBio and International Research Consortium Colors Announce Release of First-Ever HiFi Long-Read Variant Database CI
Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target MT
Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating MT
Ambry Genetics and PacBio Announces Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases CI
Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating MT
Transcript : Pacific Biosciences of California, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q1 Revenue $38.8M MT
Pacific Biosciences of California, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7 MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating MT
More news

Latest transcript on Pacific Biosciences of California, Inc.

1 week-8.16%
Current month-27.13%
1 month-25.01%
3 months-62.78%
6 months-86.05%
Current year-86.31%
More quotes
1 week
1.23
Extreme 1.231
1.39
1 month
1.23
Extreme 1.231
1.88
3 years
1.23
Extreme 1.2302
30.44
5 years
1.23
Extreme 1.2302
44.80
10 years
1.23
Extreme 1.2302
44.80
More quotes
Managers TitleAgeSince
Founder 56 00-07-13
Chief Executive Officer 56 18-07-31
Director of Finance/CFO 48 20-09-27
Members of the board TitleAgeSince
Chairman 63 13-07-17
Director/Board Member 67 12-01-17
Chief Executive Officer 56 18-07-31
More insiders
Date Price Change
24-06-28 1.26 +2.37%
24-06-27 1.231 -5.50%
24-06-26 1.303 -3.97%
24-06-25 1.356 -1.72%
24-06-24 1.38 +0.58%

Delayed Quote Börse Stuttgart, June 28, 2024 at 10:14 am

More quotes
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1.37 USD
Average target price
4.25 USD
Spread / Average Target
+210.22%
Consensus